Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study
Open Access
- 4 September 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (1) , 176-188
Abstract
Aims: Pregnancy after kidney transplantation is realistic but immunosuppressants should be continued to prevent rejection. Tacrolimus is safe during pregnancy and is routinely dosed based on whole‐blood predose concentrations. However, maintaining these concentrations is complicated as physiological changes during pregnancy affect tacrolimus pharmacokinetics. The aim of this study was to describe tacrolimus pharmacokinetics throughout pregnancy and explain the changes by investigating covariates in a population pharmacokinetic model.Methods: Data of pregnant women using a twice‐daily tacrolimus formulation following kidney transplantation were retrospectively collected from 6 months before conception, throughout gestation and up to 6 months postpartum. Pharmacokinetic analysis was performed using nonlinear mixed effects modelling. Demographic, clinical and genetic parameters were evaluated as covariates. The final model was evaluated using goodness‐of‐fit plots, visual predictive checks and a bootstrap analysis.Results: A total of 260 whole‐blood tacrolimus predose concentrations from 14 pregnant kidney transplant recipients were included. Clearance increased during pregnancy from 34.5 to 41.7 L/h, by 15, 19 and 21% in the first, second and third trimester, respectively, compared to prior to pregnancy. This indicates a required increase in the tacrolimus dose by the same percentage to maintain the prepregnancy concentration. Haematocrit and gestational age were negatively correlated with tacrolimus clearance (P ≤ 0.01), explaining 18% of interindividual and 85% of interoccasion variability in oral clearance.Conclusions: Tacrolimus clearance increases during pregnancy, resulting in decreased exposure to tacrolimus, which is explained by gestational age and haematocrit. To maintain prepregnancy target whole‐blood tacrolimus predose concentrations during pregnancy, increasing the dose is required.Keywords
This publication has 32 references indexed in Scilit:
- Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell LinesDrug Metabolism and Disposition, 2013
- Isoform-Specific Regulation of Cytochromes P450 Expression by Estradiol and ProgesteroneDrug Metabolism and Disposition, 2013
- Pharmacokinetics of Tacrolimus During PregnancyTherapeutic Drug Monitoring, 2012
- The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping testPharmacogenetics and Genomics, 2009
- Pregnancy and the KidneyJournal of the American Society of Nephrology, 2009
- Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant RecipientsTransplantation, 2008
- Pregnancy in Recipients of Solid Organs — Effects on Mother and ChildNew England Journal of Medicine, 2006
- Pregnancy in Renal Transplant RecipientsTransplantation Proceedings, 2005
- Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancyAmerican Journal of Obstetrics and Gynecology, 2005
- Estrogen Regulation of the Cytochrome P450 3A Subfamily in HumansThe Journal of Pharmacology and Experimental Therapeutics, 2004